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Abstract 
As many personal genomes are being sequenced, collaborative analysis of those genomes has 
become essential. However, analysis of personal genomic data raises important privacy and 
confidentiality issues. We propose a methodology for federated analysis of sequence variants 
from personal genomes. Specific base-pair positions and/or regions are queried for samples to 
which the user has access but also for the whole population. The statistics results do not 
breach data confidentiality but allow further exploration of the data; researchers can negotiate 
access to relevant samples through pseudonymous identifier. This approach minimizes the 
impact on data confidentiality while enabling powerful data analysis by gaining access to 
important rare samples. Our methodology is implemented in an open source tool called NGS-
Logistics, freely available at https://ngsl.esat.kuleuven.be. 
Background 
Next-Generation Sequencing (NGS) is a key tool in genomics, in particular to study inherited 
and acquired human genetic disorders [1]. Multiple projects now aim at mapping the human 
genetic variation on a large scale, such as the 1,000 Genomes Project [2], the UK 100 k 
Genome Project [3], or the Genome of the Netherlands [4]. Meanwhile with the dramatic 
decrease of the price and turnaround time, large amounts of human sequencing data have 
been generated over the past decade [5]. As of August 2014, about 2,555 sequencers were 
spread over 920 centers across the world [6]. As a result, about 100,000 human exomes have 
been sequenced so far [7]. 
Crucially, the speed at which NGS data is produced greatly surpasses Moore’s law [5] and 
challenges our ability to conveniently store, exchange, and analyze this data. Data processing 
is needed to extract reliable information from sequencing data and it can be divided into two 
major steps: primary analysis (image analysis and base calling) and secondary analysis. 
When looking for variation in the human genome, secondary analysis consists of 
aligning/mapping the reads against the reference genome and scanning the alignment for 
variation. Both raw data (i.e., the reads produced by the sequencer as well as their quality 
values, generally FASTQ files) and mapped reads (usually BAM files [8]) are large files 
occupying significant disk storage space. The collection of files resulting from the analysis of 
a single whole genome study can take up to 50Gb of disk space [9]. This raises significant 
issues in terms of computing and data storage and transfer, with off-site data transfer 
currently being a key bottleneck. 
Moreover, the analysis of NGS data also raises the major challenge of how to reconcile 
federated analysis of personal genomic data and confidentiality of data to protect privacy. In 
many situations, the analysis of data from a single study alone will be much less powerful 
than if it can be correlated with other studies. In particular, when investigating a mutation of 
interest, it is extremely useful to obtain data about other patients or controls sharing similar 
mutations. However, personal genome data (whole genome, exome, transcriptome data, etc.) 
is sensitive personal data. Confidentiality of this data must be guaranteed at all times and only 
duly authorized researchers should access such personal data. Moreover, important issues 
around informed consent also arise. What are acceptable uses of personal genomic data, in 
particular for data that has been collected primarily for a clinical purpose rather than for a 
research study? These questions are particularly hard because the legal landscape surrounding 
those questions and the interpretation of existing regulation varies from jurisdiction to 
jurisdiction, and is quickly evolving over times. We cannot resolve those questions here. 
What we do in this article is show what can be done from a technical perspective to balance 
data confidentiality and powerful data analysis for the benefit of patients and the community. 
Data sharing 
Biology and especially genomics is a data-rich environment. Tools and methods are 
constantly being improved; each method having different features compared to the previous 
versions. Since the output format of NGS sequencers has converged to standard formats over 
the past years, this gives a great opportunity to bioinformaticians to reconstruct their pipeline 
based on new methods and software to get better results. The reusability of data makes 
researchers eager to access each other’s data, but creates the additional challenge of providing 
this access at a sufficiently detailed level. We therefore aim at a solution that allows querying 
the data down to the level of aligned reads (BAM/SAM files) rather than only at the level of 
called variants (VCF files) because those may vary significantly as calling algorithms evolve. 
In addition, the number of similar cases needed to confirm a clinical or biological hypothesis 
has always been an issue. Gathering similar observations can lead to more accurate results 
and conclusions. In most situations, a change in one single nucleotide can affect the whole 
mechanism of a gene and consequently corrupt the behavior of the pathways involved, which 
could cause a disorder [10]. Therefore, comparison across multiple patients and controls is a 
key feature in studying single-nucleotide variants (SNV) and in genomics research in general. 
In practice, smaller data sets and data from routine clinical work are often not shared, 
although they also have the potential to add information that may be useful for the analysis of 
other research projects. Another example is that of building and sharing a database of variant 
frequencies in unaffected individuals, which will help excluding common variants from 
further analysis. This is especially important since common variants are highly variable 
between populations and thus regional databases will play a key role in interpreting variants 
for research and clinical purposes. Thus, some form of data sharing is highly desirable. 
Privacy 
The current European legal framework [11] on data privacy is the main influence on our 
work, but similar issues arise in the US legal framework and elsewhere. Moreover, in a 
setting of international collaboration, any solution will have to fulfill all legal requirements 
and thus focusing on the slightly more conservative EU framework may be advantageous. 
A discussion of privacy legislation is beyond the scope of this article, however a brief 
overview of some key concepts is useful to understand the motivation for our work. 
Personal data [12] is any information relating to a person who can be identified, directly or 
indirectly, in particular by reference to an identification number or to one or more factors 
specific to his physical, physiological, mental, economic, cultural or social identity. It is any 
data for which someone can link the information to the person it originated from, even if the 
person holding the data cannot make this link. 
Personal data can only be processed under three key principles of transparency, legitimacy, 
and proportionality. Transparency implies that individuals have a right to be informed when 
and how their personal data is being processed. This includes the need for appropriate 
consent for processing of the data, and the need for identifying all people processing the data. 
Legitimacy implies that personal data can only be processed for specified explicit and 
legitimate purposes and may not be processed further in a way incompatible with those 
purposes. Proportionality implies that personal data may be processed only insofar as it is 
adequate, relevant and not excessive in relation to the purposes for which they are collected 
or further processed. This includes the right to correct or withdraw information. By contrast, 
and importantly, data that is not personal – which means data that cannot be linked back to a 
specific individual – is not subject to these requirements. 
Personal genomic data is any substantive amount of genomic sequence data (e.g., human 
whole genome, exome, transcriptome, or epigenomic sequencing) that is deemed personal by 
way of being unique to each person and fixed. Importantly, this implies that removing 
classical identifiers from the data (names, social security identifiers, patient identifiers, or 
pseudonymized versions of those) is insufficient to keep the data from being personal. 
Data management 
Data control is an important and complex issue when dealing with personal data. It is 
therefore necessary to determine and know “who has access to what”. This corresponds to the 
key principle of “transparency” in the management of personal data. In most research 
institutes, it is the responsibility of the Principal Investigator (PI), the head of a group, to 
supervise the access of researchers to the data of a study, after approval by an Internal 
Review Board (IRB). In a simple scenario, the PI defines the study and assigns the researcher 
to it, and only those researchers need to access the data. However, there is often a need or 
desire to share data with other researchers from the team, and it can also often be useful to 
share the data and results with other groups within or outside the institution. Privacy 
principles do not require that the number of people accessing the data be minimized at all 
cost, but rather that the process be managed transparently, that the data be used for legitimate 
purposes, and that only people with a legitimate interest access the data. 
A potential solution to manage access to personal genomic data is the use of Access Control 
Lists (ACL). An ACL can be defined and assigned to a corresponding study, and researchers 
can then be assigned to this ACL. This feature allows to control which researcher has access 
to which study. Many operating systems support ACLs, although this is not yet a fully 
standard feature. However, for a center with several groups and several studies, it can quickly 
become difficult to maintain all these access permissions as the number of samples and 
studies increases. There is therefore a need for a data management system that can handle 
these permissions efficiently. 
Data storage and processing 
Monitoring of pipelines shows that there are several bottlenecks in terms of data storage and 
processing. Processor speed, virtual memory, and disk storage are the most frequently 
observed bottlenecks. To analyze large amounts of data, organizations will increase their 
computational power by upgrading their existing servers (scale up) and nowadays by adding 
computing and storage servers (scale out) to their hardware facilities [13]. Therefore, a well-
designed infrastructure supported by powerful computational resources and organized storage 
servers is essential. As mentioned before, by having access to similar cases and by comparing 
different studies, researchers can make more accurate conclusions. Consequently having 
access to other data across studies is necessary. However, it is often far from optimal to store 
copies of additional data sets next to the user’s own data because of the significant costs 
involved, as well as the time necessary to obtain the data and to transfer it locally. Being able 
to investigate other data sets without actually moving the data could increase research 
efficiency. 
Aims 
Our ultimate goal is to provide a way for biomedical researchers to ask high-level questions, 
such as “what is the frequency of appearance of a single mutation across the large 
population” or “how many patients with disease D have a mutation in gene G?” transparently. 
Our system also allows detailed anonymized analysis of genome sequencing data at single 
positions in the genome, for example to distinguish rare mutations from highly variable or 
poorly sequenced positions in the genome. To address all the issues described above, we have 
developed a data infrastructure, NGS-Logistics, that fulfills all requirements of a successful 
application that can process data inclusively and comprehensively from multiple sources – 
while guaranteeing privacy and security by avoiding the exchange of raw data. NGS-Logistics 
is a web-based application providing a data structure to analyze NGS data in a distributed 
way. The data can be located in any data center, anywhere in the world. NGS-Logistics 
provides an environment in which researchers do not need to worry about the physical 
location of the data. With respect to users rights, queries will be sent to each remote server. 
The host will process the request and return the results back to the main server where all the 
privacy limitations are controlled for the data. Once the results are ready, the end user can see 
the desired information. In the next section, we provide a detailed description of 
functionalities of the system and its implementation. 
Implementation 
The NGS-Logistics application package consists of three modules: 
1. Administration 
2. Query manager 
3. Primary user interface 
Figure 1 shows the components of NGS-Logistics. NGS-Logistics is designed as a multi-tier 
architecture that allows the development of a flexible and reusable application. It consists of 
three tiers: presentation, application processing, and data management. Different software 
packages are used depending on the nature of the component. Currently, Java is used for the 
administration and query manager modules, while ASP.NET is used for our user interface. 
Microsoft SQL Server is used as our database management system (DBMS). These are local 
design choices and the application could be redeployed fairly easily using other programming 
technologies. Each one of these components and their characteristics are further explained 
below. 
Figure 1 NGS-Logistics components. Users pass their queries from the NGS-Logistics web 
interface to the clients. Request are stored and scheduled in the main database. Each center 
has one database, being the only way of communication between centers and the main 
system. Centers and their databases are connected through a secured connection, to which 
only valid and trusted IPs are allowed to connect. The query manager is responsible for 
tracking and running the request, as well as collecting and returning the results to the main 
system. 
Administration 
The administration module mainly focuses on controlling the access rights of the users. It is 
the place where the administrator sets up access control among users, so that confidentiality 
of personal genomic data can be guaranteed. The system administrator can also control the 
type and volume of queries that the different users are allowed to submit. The user interface 
is designed in such a way that the complexity of users’ access controls is hidden. For finer 
control over users, users can be assigned roles at different levels (Figure 2). 
Figure 2 NGS-Logistic users types and their access level. 
The system administrator defines the centers and their local admins. Local admins are 
responsible for ensuring that the sample list is kept updated and the samples are assigned to 
the authorized PIs. They also manage the users’ accounts, assign samples to data sets, and 
allocate data sets to users or groups of users. Data sets can be private or public (i.e., 
accessible to all the users of the system) depending on the characteristics of the samples that 
they contain. 
Sample list 
The sample list is the list of all files that each center makes available through NGS-Logistics. 
The sample list can be updated either automatically or manually by the local admin. Several 
fields such as the “Sample Local Name”, “PI Name”, “Sample Type”, and “Sample 
Reference version” are compulsory for each sample. At the time of insertion, NGS-Logistics 
automatically assigns an internal Sample ID to each sample to pseudonymize the actual name 
(Sample Local Name) given to the sample by the owner from the rest of the users. (Note that 
pseudonymization does not stop the data from being personal because the genome or exome 
sequence is unique to each individual.) Then it uses the “PI Name” and “Sample Type” fields 
for recognition of the type of sample (Research or Diagnostics) and assigns them to the 
owner of the sample (PI Name). The “Sample Reference Version” shows the version of the 
human genome build to which the sample has been aligned. Since samples can be aligned to 
different builds of the human genome, the system will use this information to aggregate query 
results. To do so, we use the UCSC LiftOver database [14]. 
Query manager 
The query manager is a component that picks up the request at each center, runs the task, 
gathers the results, and returns them back to the main system. Since there are different 
infrastructures and software packages in different centers, we have tried to keep the query 
manager as simple as possible. To establish a connection between the server and clients, we 
only need to configure the query manager by changing a small list of parameters, such as the 
address of the executable applications and of the data (BAM files). As we need to integrate 
all results from different sources, we query BAM files with GATK [15]. The output looks 
like a standard VCF file [16], which is exported from the different centers to the main system. 
Standard GATK variant caller output has the following fields: Chromosome, Position, dbSNP 
ID, Ref, Alt, Qual, Filter, Info Format, and Format Values. 
User interface 
The user interface plays an important role in the success of an application. Well-designed 
user-friendly interfaces have a great impact on the users’ activities. Therefore, we have tried 
to make the interface as simple and intuitive as possible. The NGS-Logistics interface allows 
the users to submit their queries, track them, and visualize the results. To further explain this, 
we divide the interface into three categories: user settings, query builder, and results. 
User settings 
User settings allow users to alter their information, create their own data sets, assign samples 
(to which they have authorized access) to these personal data sets, and activate their data sets. 
Users can choose the data set they want to investigate from the list of those they have 
authorized access. This procedure is called Data Set Activation. Activating a data set is 
important: if no data set is activated, no detailed results will be available (in the results 
section, we will discuss what kind of detailed information). This feature is part of our security 
system and privacy agreement. In this way, we guarantee that users can only see information 
they are authorized to see. Besides detailed information, some summary values (such as the 
total number of appearance of a variant or average coverage) are displayed. 
Users can also ask for access to samples and data sets from other groups. In this case, the 
owner of the data must review the request and grant access to the data or not. 
Query builder 
Two types of queries are available: point and area statistics. GATK is used to call variants for 
both types of queries but results and statistics are shown slightly differently for each type of 
query. Since GATK provides two variant callers, users can choose between HaplotypeCaller 
and UnifiedGenotyper. In point queries, users must fill in the chromosome and position and 
have the possibility to genotype reference sites (allSitePLs); whereas in area queries, they 
have to provide the chromosome number and start and end positions, or a gene name. After 
submitting the query, a unique request ID is assigned to the request. In the background, the 
system automatically sends the query to the centers and waits for results. Meanwhile, through 
the request tracking option, users can see the status of the request. Since the process really 
depends on the facilities and workload of each center, we cannot estimate the duration of 
each process but display the progress by center. 
Results and Discussion 
All functionalities of NGS-Logistics will be illustrated by querying one gene. Another 
example will demonstrate how NGS-Logistics can help interpreting variants. A demonstration 
run was performed and successfully analyzed samples located on two centers (KU Leuven 
and UZ Leuven) with approximately 1500 exome samples in total. 
Use case one 
We use the example of SMARCA2, a gene located on Chromosome 9, whose heterozygous 
mutation causes Nicolaides-Baraitser syndrome [17]. We start with the area query. An area 
can be queried using a gene name or a region (defined by chromosome number and start and 
end positions). The area query results section is divided into three sections: “Summary”, 
“Samples to Positions”, and “Positions to Samples”. The top part of each section describes 
the query and includes, if possible, links to well-known online databases, such as the UCSC 
and Ensembl genome browsers. The “Summary” section displays the total number of samples 
queried in each center and the total number of samples to which they have access. Results can 
be investigated by checking the list of available mutations per sample (“Samples to 
Positions” section) or by checking the list of all mutations for the selected region, how 
frequently they occur, and which genotypes are observed in all samples from all centers 
(“Positions to Samples” section, Figure 3). We refer to all samples from all centers as the 
“Whole Population”. Note that the “Whole Population” contains the samples from the active 
data set. One of the SNVs reported in SMARCA2 has the dbSNP id: rs281875187 
(chr9:2115841, build 19). As shown in Figure 3, this SNV is not observed in any sample 
from the active data set, but in the whole population, one sample is heterozygous. If other 
samples were found with this mutation, it would be of direct interest to a researcher to contact 
the PI responsible for this sample, for example, to investigate whether or not this patient is 
affected by Nicolaides-Baraitser syndrome to confirm or weaken the hypothesis of 
association between Nicolaides-Baraitser syndrome and SMARCA2 mutations; or to collect 
biological samples from patients for further biological studies. 
Figure 3 NGS-Logistics area query results page (Position to Sample section) for 
SMARCA2. Results demonstrate that at the selected position (chr9:2115841, build 19) a G to 
A mutation can be observed with heterozygous genotypes. The graph shows the differences 
between the active data set and the whole population. Users can see the list of samples to 
which they have access and related information in the detail table (if any available). For 
further inquiries about the selected position links to the public databases are provided. Also 
users are able to submit a single point query if they are interested to see more details about 
the selected position. 
The single point query allows users to investigate a single position. The single point query 
results page is divided into four sections: “Summary”, “Detail”, “Statistics”, and “Sample to 
SNV”. Similarly to the area query, the top part of each section contains information related to 
the query, as well as links to dbSNP and the UCSC and Ensembl genome browsers. The 
“Summary” section displays information on the total number of samples queried in each 
center and summary results (number of samples genotyped as or different to homozygous 
reference, minimum, maximum and average quality scores). The “Detail” section contains the 
GATK output for the samples of the active data set. Results are available for download. The 
“Statistics” section provides an overview of the different genotypes and their quality values. 
Graphs are divided into three sets of data: the active data set, control data set and the whole 
population (Figure 4). Control data set includes unaffected, unrelated individuals. Usually 
these individuals are either unaffected parents or unaffected siblings of affected patients. As 
such they might carry one pathogenic mutation. Each center can provide a list of these 
individuals. Minimal allele frequency (MAF) is calculated to each data set. A call is assigned 
to each sample and by default no quality filtering is performed by NGS-Logistics. However 
users are free to select good quality variants according to quality, depth, genotype quality 
and/or PL values. Finally, the section “Sample to SNV” is the demonstration of the relation 
between available genotypes and samples (Figure 5). Samples are clustered based on their 
genotype, dbSNP ID, center, and PI name. Every sample is assigned a pseudonymized 
System Sample ID, different from the real sample ID. This identifier can be used to request 
access to the sample details. Samples for which the user is not allowed to see the details are 
colored in grey. This system allows the quick identification of the person to contact to get 
access to a relevant new sample. 
Figure 4 Single Point Query result page (Statistic section) for chr9:2115841. The query 
of chr9:2115841 shows that only one sample is polymorphic at this position. All samples that 
can be genotyped at this position from the active data set, control data set and whole are 
homozygous reference. The MAF of this variant in each data set is thus very low. 
Figure 5 Single Point Query results page (Sample to SNV section) for chr9:2115841. 
Those samples that have a mutation are clustered based on their genotypes, dbSNP ID, 
Center, and Sample Owner name. Samples are labeled by their system ID, which is different 
from the actual sample name, and are color-coded according to the user’s active data set (red 
= active/accessible, grey = inactive/inaccessible). 
Use case two 
The variant analysis of three patients with congenital disorder of glycosylation revealed two 
good quality heterozygous variants (chr9:108363420 and chr9:108397495, build 19) in the 
fukutin gene, responsible for muscular dystrophy-dystroglycanopathy. Since fukutin is a 
recessive gene disorder, two heterozygous variants on different alleles or one homozygous 
variant could cause the disease. The use of NGS-Logistics showed that both variants were 
reliably genotyped as heterozygous in 22 individuals and had a MAF of 0.05 and 0.03 in the 
control data set and the whole population respectively. The “Sample to SNV” graphs (Figure 
6) showed that the same 22 individuals carried both variants in a heterozygous state 
indicating that the variants are on the same allele. Consequently, the combination of the two 
variants found in three of our patients cannot cause the disease. 
Figure 6 Single Point Query results page (Sample to SNV section) for chr9:108363420 
and chr9:108397495, build 19. For both positions variants genotyped with PL < 70 are 
filtered before counting polymorphic samples. Since all 22 individuals carried both variants 
in a heterozygous state, we are able to conclude that the variants are on the same allele. 
Conclusions 
There is currently no comprehensive solution for personal genomic data sharing. The 
Database of Genotypes and Phenotypes (dbGaP) [18] and the European Genome-phenome 
Archive (EGA) allow the exchange of personal genomic data. However, some important 
limitations remain. The process of securing approval for data access is time consuming and 
involves significant administrative overhead because the process involves legal contracting 
between the requesting institution, dbGaP or EGA, and the institution providing the data. 
dbGaP or EGA acts as broker between institutions and maintains the data sets under escrow 
until approval of the requests. Data transfer to the receiving party, reprocessing of the data, 
and maintenance of the data locally represent significant hurdles for non-specialists and 
require significant computational resources. The need for reporting and project closure adds 
further to the administrative overhead. As a result, there is a major barrier to using those 
resources and the available data is not being exploited to its full extent. It also slows down the 
adoption of those systems by institutions that could be providing significantly more data than 
is happening in practice. 
Another solution for data sharing is to rely on vendor solutions, such as Illumina BaseSpace, 
or more recently Google Genomics. Well-integrated vendor solutions are tempting because 
they could allow easy access to data sets from collaborators spread across the world through 
cloud-based solutions. However, it is unclear how such solutions will support a privacy-
enhancing framework beyond leaving access decisions entirely at the responsibility of 
individual researchers. Moreover, such solutions could present a significant risk of network 
effect. If significantly more and more data becomes available through a given vendor, this 
solution will acquire a major advantage over the competition. Given broadly similar feature, 
the network with the most data is by far the most valuable because it allows answering more 
research questions. A dominant network could possibly wipeout all significant competition, 
and gain a permanent lock-in over significant amounts of personal genomic data worldwide. 
Therefore, issues of platform interoperability and data freedom are essential when 
considering vendor solutions for personal genomic data sharing. 
Further access to the samples by providing a researcher with direct access to a given samples 
after request is subject to the standard process. Does the consent provided by the patient or 
guardian allow for legitimate access by the third party? Or is additional consent or approval 
by the IRB necessary? This process cannot be automated at this point because the answer 
depends on the specific details of the request and on the legal framework imposed by the 
jurisdiction or institution. However, the fact that all users and requests are tracked provides a 
high level of transparency, which should ease this process greatly. 
A key design choice in NGS-Logistics has been to provide data analysis at the level of aligned 
reads (BAM files) rather than called variants (VCF files). While deploying a system handling 
only VCF files might be easier, we believe that for detailed analysis of a single nucleotide 
position it is desirable to use a uniform assessment of variants across all samples, which will 
be difficult to guarantee for legacy VCF files produced at different times using different 
pipelines. Besides querying BAM files allow the genotyping of reference calls, which are 
often not included in standard VCF files. Knowing whether a sample is homozygous 
reference at one position or whether the position is not covered is important since it allows a 
better assessment of the MAF. 
One way in which the power of the system can be increased is by making healthy control 
population sets available through the system. Currently, the “Whole Population” contains all 
samples available in the system regardless of clinical diagnosis. Once a relevant mutation has 
been identified, samples can be tracked down, and clinical information can be gained about 
these samples. However, the “Whole Population” will contain samples that can be considered 
“cases” as well as “controls” without distinction. This prevents us from implementing any 
form of association scoring in NGS-Logistics. So far we have one Control population but it be 
useful to add phenotypic information in the next phase, so that association scores can be 
calculated for mutations between the active data set and a control data set with respects to 
their phenotype. Promising mutations can then be evaluated in details in the system. 
Similarly, another difficulty for any association analysis is that samples from the same patient 
could be processed at different sites (i.e., seen by physicians at different clinical centers) with 
no communication that these samples are identical. This would skew any statistics of the 
presence of variants in the population. Using a hash derived from the genome of the patient, 
which would identify each patient uniquely and thus allow recognition of the fact that the 
same patient is present at two centers would alleviate this problem. However, it is unclear 
how such a hash could be derived from noisy genome information and also such an approach 
goes against the idea of minimizing the amount of personal information shared because it 
provides a unique identifier for each patient. Our approach allows drilling down through the 
data to the lowest level and contacting PIs responsible for different patients and therefore 
eventually identifying that different records correspond to the same patient. 
Finally, the main direction for further development of our system is that it currently does not 
support clinical information. There are important technical issues that make handling clinical 
information challenging. Clinical information is often managed and transferred separately 
from sequencing data. Researchers may often have sequencing data, but little clinical 
information beyond a few overly broad labels (e.g., tumors vs. controls), which makes query 
by others difficult. In practice, clinical information in genomic research project is often 
managed in an unstandardized way without reliance on structured information, such as 
ontologies. Even if data is described in a structured way, there are currently only limited 
options to cover all clinical domains beyond Unified Medical Language System (UMLS) or 
Systematized NOmenclature of MEDicine Clinical Terms (SNOMED), which have important 
limitations. Extracting clinical information automatically from hospital information systems 
remains extremely challenging and will be done differently in each center. For these reasons, 
integrating clinical information into NGS-Logistics remained beyond the scope of this article. 
Developing a full clinical information management system is unrealistic and would be too 
cumbersome for users. A more realistic direction is to provide a simple way to annotate 
samples with either free text or, better, with Resource Description Framework (RDF) triples 
(or similar concepts) that allow annotation using properly referenced ontologies. Both 
functionalities should be present so as not to exclude users that can only provide free text 
annotation. Text search and SPARQL-like (SPARQL Protocol and RDF Query Language) 
querying would then allow identifying relevant samples based on clinical information. This 
will make it possible to carry out queries such as “which mutations are significantly more 
frequent in clinical population A versus clinical population B across multiple centers?” 
The key concept in NGS-Logistics is to let users query SNVs across data sets in multiple 
centers. Users get a full description of the results for the samples to which they have 
authorized access, while getting relevant summary information for other samples. This 
summary information is sufficient to carry out key research tasks, such as identifying relevant 
mutations in a patient population. The footprint on personal genomic data from other patients 
is kept to a bare minimum. The frequency of mutation at a given position in the “Whole 
Population” is not personal data and thus not subject to restrictions. The ability to identify a 
specific pseudonymized sample carrying a specific mutation provides stricto sensu access to 
personal genomic data. However, the amount of information is kept minimal (one single 
base-pair position at a time), the identifier is pseudonymized (to avoid any possibility of 
direct identification), and all users and requests are tracked by the system. The interest of 
broadly allowing bona fide researchers to identify relevant samples for further research or to 
support clinical diagnosis fulfills the legitimacy principle of data privacy. The fact that users 
and requests are tracked at all times contributes to the transparency principle. Finally, the fact 
that information about samples beyond the authorized ones is kept to non-personal summary 
statistics, except for a single backlink through a pseudonymous identifier, contributes to the 
proportionality principle. As such, we believe our system represents a best effort to enforce a 
high-level of data protection while providing a powerful solution for clinical genomic 
research and diagnosis support. 
Availability and requirements 
• Project name: NGS-Logistics 
• Project home page: https://ngsl.esat.kuleuven.be 
• Operating system(s): Platform independent 
• Programming language: ASP.Net and Java 
• NGS-Logistics has been tested on the following browsers: Google Chrome, Mozilla 
Firefox and Safari 
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